Inhibikase Therapeutics IKT

$ 1.97 -0.76%

Quarterly report 2024-Q3
added 11-14-2024

Inhibikase Therapeutics Balance Sheet 2011-2024 | IKT

Annual Balance Sheet Inhibikase Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-8.64 M	-6.84 M	-	-13.9 K	355 K	-146 K	-	-	-	-	-	-	-
Long Term Debt	382 K	205 K	-	-	275 K	-	-	-	-	-	-	-	-
Long Term Debt Current	150 K	146 K	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	275 K	-	-	-	-	-	-	-	-
Total Current Liabilities	3.44 M	3.7 M	4.05 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	3.53 M	3.9 M	4.05 M	5 K	4.53 M	3.62 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	2.33 K	1.43 M	262 K	-	-	-	-	-	-	-
Retained Earnings	-66.9 M	-47.9 M	-29.8 M	-	-12.2 M	-6.46 M	-	-	-	-	-	-	-
Total Assets	14.5 M	24.9 M	42.5 M	14.8 K	38.3 K	2.85 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	9.17 M	7.19 M	40.8 M	14 M	-	-	-	-	-	-	-	-	-
Book Value	11 M	21 M	38.4 M	9.78 K	-4.49 M	-778 K	-	-	-	-	-	-	-
Total Shareholders Equity	11 M	21 M	38.4 M	9.78 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Inhibikase Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	25.6 K	58.3 K	-	121 K	150 K	178 K	-	232 K	-	-	249 K	249 K	249 K	1.24 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	4.91 M	3.73 M	4.29 M	3.53 M	2.86 M	2.88 M	2.84 M	3.9 M	3.45 M	4.49 M	4.38 M	4.05 M	2.71 M	2.16 M	3.84 M	5 M	5 M	5 M	5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	143 K	1.25 M	2.33 M	2.33 M	2.33 M	2.33 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-82.3 M	-76.5 M	-71.6 M	-66.9 M	-62.7 M	-58.1 M	-52.3 M	-47.9 M	-43.6 M	-39.1 M	-34.5 M	-29.8 M	-24.8 M	-20.3 M	-17.7 M	15 M	-15 M	-15 M	-15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	4.38 M	8.83 M	11.1 M	14.5 M	17.9 M	22.3 M	28.2 M	24.9 M	28.6 M	34 M	38.4 M	42.5 M	45.9 M	49.2 M	11.9 M	14.8 M	14.8 M	14.8 M	14.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	913 K	3.09 M	2.35 M	9.17 M	14.9 M	1.91 M	3.96 M	7.19 M	5.78 M	32.2 M	36.6 M	40.8 M	44.8 M	46.8 M	9.61 M	14 M	14 M	14 M	14 M	18.5 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-531 K	5.1 M	6.78 M	11 M	15 M	19.5 M	25.3 M	21 M	25.1 M	29.5 M	34 M	38.4 M	43.2 M	47.1 M	8.04 M	9.78 M	9.78 M	9.78 M	9.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-531 K	5.1 M	6.78 M	11 M	15 M	19.5 M	25.3 M	21 M	25.1 M	29.5 M	34 M	38.4 M	43.2 M	47.1 M	8.04 M	9.78 M	9.78 M	9.78 M	9.78 M	-4.49 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency